The study of the diuretic activity and pharmacotechnological properties of a dry extract of Salvia sclarea L. growing in Tajikistan

Abstract

Aim. To study the pharmacological activity of a dry extract of clary sage (DECS) growing in Tajikistan and its pharmacotechnological properties as basic stages in the development of the composition and technology of hard gelatin capsules with its content. Materials and methods. For the studies, we used DECS standardized by the content of the total amount of flavonoids and hydroxycinnamic acids. The quantitative content of the total amount of flavonoids was not less than 13.0 % calculated with reference to apigenin, and the quantitative content of the total amount of hydroxycinnamic acids was not less than 1.2 % calculated with reference to rosmarinic acid. The pharmacotechnological properties of DECS were studied according to methods of the State Pharmacopoeia of Ukraine (SPhU). Results and discussion. During screening, all doses of DECS studied showed a moderate diuretic activity. Thus, when using DECS in the dose of 100 mg/kg, the relative volume of the urine excreted by rats for 5 hours increased by 1.9 times, in the dose of 200 mg/kg – by 2.0 times, in the dose of 300 mg/kg – by 1.8 times compared to the same indicator in the negative control group (p˂0.05). When studying the complex of pharmacotechnological properties, it was found that DECS was a finely dispersed amorphous powder with particles of isodiametric form. DECS had an average bulk weight of 0.515 ± 0.002 g/mL, and the fluidity assessment showed that DECS had a very poor flowability, which value in the vibration mode of the device was 2.8 ± 0.1 g/s. According to the study of the fractional composition, DECS had a clearly expressed fine fraction with a particle size of less than 0.25-0.09 mm 84.68 %. Conclusions. Taking into account the results of the study of the diuretic activity and scientific literature data on the spectrum of the pharmacological activity of Salvia sclarea L, it is rational to consider DECS as a potential combined agent for enhancing the diuretic effect or in diseases of the urinary system accompanied by edema and inflammatory processes. The study of the pharmacotechnological indicators of DECS allows predicting the need to use certain groups of excipients to develop the composition and technology of capsules with its content, namely antifriction substances to improve fluidity and disintegrants to improve capsule disintegration, as well as substances that contribute to the compaction of bulk mass and moisture-regulating agents.